# Study Evaluating The Safety and Tolerability of HTC-867 in Healthy Japanese Subjects

> **NCT01268124** · PHASE1 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 56 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** HTC-867

## Key facts

- **NCT ID:** NCT01268124
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2010-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01268124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01268124, "Study Evaluating The Safety and Tolerability of HTC-867 in Healthy Japanese Subjects". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01268124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*